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Abstract Activation of the α-secretase processing pathway
of amyloid precursor protein (APP) is recognized as an
important mechanism which diverts APP processing from
production of beta-amyloid (Aβ) to non toxic sAPPα,
decreasing Alzheimer’s disease (AD) plaque formation and
AD-associated cognitive deficits. Two potent classes of
PKC modulators can activate the α-secretase pathway, the
benzo/indolactams and bryostatin/bryologues. While both
modulate PKC-dependent APP processing, no direct com-
parisons of their relative pharmacological potencies have
been accomplished which could assist in the development
of AD therapies. In this study, we measured the activation of
α-secretase APP processing and PKC-α, -δ, and -ε induced
by the benzolactam-APP modulator TPPB and bryostatin-1 in
the neuroblastoma cell line SH-SY5Y which expresses APP
and α- and β-secretase processing mechanisms. Bryostatin-1
produced a more rapid, potent, and sustained activation of α-
secretase APP processing than TPPB and selectively activated
PKC-δ and PKC-ε. Although TPPB also activated α-
secretase, its potency was approximately 10- to 100-fold
lower, possibly reflecting lower PKC-δ and -ε activation.
Because bryostatin-1 is a highly potent PKC-δ and -ε activator
which activates α-secretase APP processing, further charac-
terization of bryostatin-1/bryologues may help refine their use
as important tools for the clinical management of AD.
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Introduction
Despite more than a century of intensive research on Alz-
heimer’s disease (AD), few effective treatment options have
been developed (Galimberti and Scarpini 2011). Currently,
AD is treated using cholinesterase inhibitors (donepezil, gal-
antamine, rivastigmine, tacrine) which support cholinergic
signaling, and memantine, an N-methyl-D-aspartate receptor
antagonist, which reduces glutamate-dependent excitotoxic-
ity, Ca2+ influx, and oxidant stress in neurons (Tayeb et al.
2012). Both drug classes provide only marginal benefit, and
more effective therapies are still required to treat AD. AD
progression is associated with the appearance of extracellular
“plaques” which contain β-amyloid (Aβ), as well as neurofi-
brillary tangles consisting of hyper-phosphorylated tau pro-
tein. Mechanistically, β-amyloid plaques are thought to
provoke progressive neurodegeneration and behavioral and
cognitive disturbances in AD.
Several other drug classes, e.g., non-steroidal anti-
inflammatory drugs (NSAIDs) and “statins,” inhibitors of
HMG-coA reductase, may also reduce formation and
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persistence of Aβ and have been suggested as potential
adjuvant therapies for AD (Fonseca et al. 2010). Mechanis-
tically, both statins and NSAIDs inhibit Rho G, Rho-kinase
(ROCK), and Rac-1 activity, implying that these pathways
may contribute to Aβ accumulation, AD plaques, and de-
mentia, at least in mouse models of AD (Kurata et al. 2011).
While intriguing, the introduction of statins and NSAIDs as
adjuvant therapies in AD still requires clinical validation but
may provide important clues for AD therapy (Hoyer and
Reiderer 2007). Additionally, several phytochemicals (can-
nabinoids, physostigmine, and nicotine) and dietary modu-
lators (curcumin, resveratrol, gingko, saffron, lemon balm,
sage) have also been suggested as possible treatments for
AD based on their effects on cholinergic signaling, oxidant
formation, and processing of amyloid precursor protein
(APP) (Nitsch et al. 1992; Howes and Perry 2011). The
proteolytic processing of APP into extracellular Aβ deposits
involves the action of β- and γ-secretases. Based on this
understanding of APP processing, inhibitors of both β- and
γ-secretases have been evaluated as Aβ plaque-suppressing
therapeutics in AD.
Inhibitors of β-secretase (BACE-1) include dipheny-
lurea, derivatives of hydroxyethylamine, and celastol, all
of which at least partly block conversion of APP to Aβ.
Τhese drugs have been extensively studied in AD therapy
(Huang et al. 2010; Paris et al. 2010; Truong et al. 2010).
While effective against β-secretase in vitro (Hills and Vacca
2007), these inhibitors have been less effective in in vivo/
clinical AD studies. Similarly, γ-secretase modulators
(“GSM”) have been proposed to reduce Aβ accumulation
(Imbimbo and Giardina 2011). Several candidate GSMs,
“DAPM”, and “DAPT” (Czvitkovich et al. 2011), NSAIDS
(Ibuprofen, flurbiprofen), and purine analogs (Rivkin et al.
2010) were proposed as γ-secretase modulators, but clinical
trials have been unsuccessful and a recent clinical trial with
semagacestat (LY-450139) was halted because of potentially
accelerated dementia.
While β- and γ-secretases cooperatively convert APP
into Aβ, α-secretase is a competing pathway for APP which
diverts the substrate APP into production of sAPPα, which
is non toxic and effectively prevents the formation of amy-
loid plaques and AD-related dementia. α-secretase is actu-
ally a family of several proteins including tumor necrosis
factor-α converting enzyme (“TACE”), a disintegrin and
metalloprotease (‘ADAM’)-17 (Black et al. 2003), and
ADAM-9, -10, and -19 (Asai et al. 2003; Tanabe et al.
2007). While many strategies are aimed to block disease
progression in animal models of AD, activation of α-
secretase processing of APP remains highly attractive be-
cause it competes with the β- and γ-secretase pathways for
APP. Several cell signaling modules can activate α-secretase
processing of APP, including Mints/X11s and Nogo-66
receptor (which bind APP), Rho GTPases, reticulon
(RTN)-3 and -4, and the prolyl isomerase “Pin1.” These
mechanisms suppress the formation of Aβ both in vitro
and in vivo (Tang and Liou 2007) but have not yet been
exploited therapeutically (Ikin et al. 2007).
One of the most potent and effective means of triggering
α-secretase is by protein kinase C (PKC) activation. Several
drugs which modulate PKC isoenzyme activity, particularly
the PKC-δ and PKC-ε isoforms, potently activate α-
secretase processing of APP, generating the non toxic
sAPPα and preventing Aβ formation. Currently, PKC acti-
vators may represent the most important, novel, and specific
treatments for AD. At least two important classes of agents
can activate PKC-dependent APP processing at relatively
low (μM to nM) doses: (1) the benzolactam/indolactams
and (2) bryostatin-1 and related bryologues.
TPPB is a novel cell-permeable benzolactam-derived
PKC activator (Ki011.9 nM for inhibition of phorbol
12,13 dibutryrate binding to PKC-α) which enhances
sAPPα secretion in fibroblasts and PC12 neuronal cells
(Ibarreta et al. 1999). The bryostatins are a family of ~20
natural marine cyclic macrolides (Pettit et al. 1982) with
potent anti-cancer properties. Bryostatin-1 is a powerful
PKC activator, potently stimulating PKC-δ and -ε isozymes
at sub-nanomolar concentrations (Szallasi et al. 1994).
Emerging evidence suggests that bryostatin-1 can enhance
memory and cognition and helps stabilize or even reverse
AD-associated dementia (Sun and Alkon 2010). Although
bryostatin-1 and TPPB share similar targets, pharmacology,
and applications in AD research, a direct comparison of
benzolactam and bryostatin-1 as APP modulators has not
yet been carried out in an in vitro neuron model, which
could provide important insights on their use in
mechanism-based AD therapy. This current study evaluates
dose- and time-dependent activation of α-secretase (sAPPα
secretion) and PKC-α, -δ, and -ε isoform activation in the
SH-SY5Y cell line in response to bryostatin-1 and TPPB.
Materials and Methods
Test Agents Bryostatin-1 in ethanol stock solutions was
provided by Aphios Corporation (Woburn, MA, USA).
The benzolactam APP modulator TPPB [(2S,5S)-(E,E)-8-
(5-(4-(trifluoromethyl) phenyl)-2,4-pentadienoylamino)
benzolactam] (CAS#497259-23-1) was purchased from
Reagent 4 Research LLC (Hangzhou, China) and was dilut-
ed in ethanol. All ethanol concentrations in this study were
below 0.1 % in cellular assays.
Cells and Cell Culture SH-SY5Y neuroblastoma cells
(Kohl et al. 1980) were selected for studying neuronal
APP metabolism because they retain a neuronal phenotype,
possess a full complement of APP-processing and signaling
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pathways, and have been well characterized in AD studies
(Canet-Aviles et al. 2002). SH-SY5Y neuroblastoma cells
were obtained from American Type Culture Collection
(Manassas, VA, USA) and were maintained in DMEM
(4.5 g/L glucose), 10 % fetal bovine serum (FBS), and
1 % antibiotic/antimycotic. SH-SY5Y cells were subcul-
tured into six-well polystyrene tissue culture dishes and
grown to confluency prior to use in APP processing and
PKC activation studies.
Treatment Protocols Cells were grown to confluency in
10 % serum-supplemented medium. Prior to experiments,
culture medium was replaced with serum and protein-free
(0 %) medium for 2 h before drug treatments to remove
APP/sAPPα present in FBS and to permit filter concentra-
tion of sAPPα. Dilutions of bryostatin-1 or TPPB were
added to serum-free culture medium at various concentra-
tions and treatments maintained for 3 h, except in time
course experiments where several time points up to 24 h
were taken. Pilot studies showed no change in SH-SY5Y
appearance, attachment, or cell density for at least 24 h
under these conditions.
Measurements of α-Secretase Activity (Production of
sAPPα) Activation ofα-secretase was monitored by measuring
the secretion of the soluble 93-kDA cleavage product of APP
(“sAPPα”) generated by α-secretase. After drug treatments,
serum-free culture medium was harvested and centrifuged at
14,000×g for 15 min across a 10-kDA cutoff Amicon
membrane ultra-centrifugal filter (Millipore Corporation,
Billerica, MA, USA). Concentrated supernatants con-
taining sAPPα were resuspended in 50 μL of Laemmli
sample buffer, heated (100 °C, 5 min), electrophoresed
on 10 % SDS/PAGE gels, and immunoblotted to
0.2 μm nitrocellulose membranes to quantify sAPPα.
Membranes were blocked with 5 % nonfat dry milk/
PBS for 1 h to prevent nonspecific antibody binding.
Blocked membranes were incubated overnight at 4 °C
with 1:500 diluted 6E10 monoclonal antibody in 0.1 %
milk powder (Covance, Dedham, MA, USA). 6E10 an-
tibody (Covance, Berkeley, CA, USA) is raised against
the sequence DAEFRHDSGYEVHHQK which is com-
mon to APP, β-amyloid, and sAPPα. sAPPα corre-
sponds to 90 kDA 6E10 antibody reactive band
recovered from the medium-soluble fraction (Yang et
al. 2007). After washing, membranes were incubated
for 2 h at 25 °C with horseradish peroxidase (HRP)-
conjugated anti-mouse IgG secondary antibody (diluted
1:5,000, Sigma). HRP-bound signal was detected using
enhanced chemiluminescence (“ECL plus,” GE Health-
care, UK) to expose X-ray film (SRX101 film, KON-
ICA Corp.). Band intensities were quantified by
densitometry analysis using an HP Scanjet 3970
Densitometer and Image-J image analysis system soft-
ware (Ver. 3.0, NIH). Control band densities on each
blot (sAPPα, PKC-α, -d, or -ε) were set as 100 %, and
changes in recovery of target proteins in response to
drug treatments were expressed as the normalized per-
cent of each control. All experiments were performed in
triplicate (n03).
Activation of PKC Isoforms by TPPB and Bryostatin-
1 Measurements of cytosolic and membrane-associated lev-
els of PKC-α, -δ, and -ε isoenzymes were used to assess
PKC translocation in response to bryostatin-1 or TPPB as
described by Racchi et al. (1994) with modifications (Ibar-
reta et al. 1999). Briefly, following treatments, cells were
washed twice with ice-cold PBS, scraped using a rubber
policeman, and collected by low-speed centrifugation at
1,500×grpm for 5 min. These pellets were resuspended
and vortexed in “homogenization buffer” (50 mM Tris
HCl [pH 7.4], 150 mM NaCl, 1 mM EDTA, and mixed
protease inhibitors (Sigma)). Cells were centrifuged at
15,000×g for 30 min. These supernatants were reserved as
“cytosol” fractions. Pellets from this spin were homoge-
nized in this same buffer containing 1.0 % Triton X-100/
1.0 % NP-40, sonicated, incubated on ice (45 min), and
centrifuged again at 15,000×g for 30 min. The supernatants
from this batch were “membrane” fractions. After protein
determination (BCA method, Biorad), protein samples were
diluted in 2× Laemmli sample buffer, heated (100 °C,
5 min), electrophoresed on 10 % SDS/PAGE gels, and
immunoblotted to 0.2 μm nitrocellulose for probing with
1:500 diluted anti-PKC-α [antibody h-7, sc-8393], -δ [anti-
body G-9, sc-8402], and -ε [antibody E-5, sc-1681] anti-
bodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
H-7 antibody is a mouse monoclonal antibody raised against
amino acids 645–672 on human PKC-α which recognizes a
single 80-kDA PKC-α isoform. G-9 antibody is a mouse
monoclonal antibody raised against amino acids 647–673 of
rat PKC-δ which recognizes a single 78-kDA band, and E-5
antibody is a mouse monoclonal antibody which was raised
against amino acids 705–737 of human PKC-ε and rec-
ognizes a single 90-kDA PKC-ε band. PKC isoform
bands were visualized using HRP-conjugated 2° anti-
body (1:5,000) with ECL plus (GE Healthcare, UK)
with SRX101 film. Band intensities were quantified by
densitometric analysis using an HP Scanjet 3970 Den-
sitometer and Image-J image analysis system software
(Ver. 3.0, NIH).
Statistical Analysis All data are presented as mean ± stan-
dard deviation and were analyzed by one-way ANOVAwith
Dunnett’s post-testing (Graphpad Instat 3 Software, San
Diego, CA, USA). A value of p<0.05 was considered as
statistically significant.
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Results
Induction of sAPPα Secretion by Bryostatin-1 and TPPB in
SH-SY5Y Neuroblastoma Cells sAPPα secretion induced by
treatment of SH-SY5Y neuroblastoma cells with different
concentrations of bryostatin-1 or the benzolactam modulator
TPPB was initially studied at 3 h. Bryostatin-1 significantly
induced sAPPα release at 10−7 M (**p<0.01), 10−8 M (**p
<0.01), 10−9 M (*p<0.05), and 10−10 M (*p<0.05). TPPB
also induced sAPPα release, but to a lesser extent and only
at 10−7 M (p<0.05) and 10−8 M (p<0.05) (Fig. 1).
A time course study in SH-SY5Y neuroblastoma cells
induced by bryostatin-1 and TPPB showed that, at 10−7 M,
bryostatin-1 significantly increased the release of sAPPα at
3 h (**p<0.01); TPPB was able to significantly increase
sAPPα at 6 h (*p<0.05) (Fig. 2a). At 10−8 M, bryostatin-1
significantly induced sAPPα release at 3 h (**p<0.01), 6 h
(**p<0.01), and 12 h (*p<0.05). At this dose, TPPB only
significantly increased the release of sAPPα at 6 h (*p<
0.05) (Fig. 2b). Bryostatin-1 at 10−9 M induced the signif-
icant release of sAPPα at 0.5 h (*p<0.05), which persisted
at 1 h (**p<0.01) and 3 h time points (**p<0.01). By
comparison, TPPB only induced the significant release of
sAPPα at 3 h (*p<0.05) (Fig. 2c). Bryostatin-1 at 10−10 M
induced the significant release of sAPPα at 3 h (**p<0.01);
however, TPPB at 10−10 M did not significantly increase the
release of sAPPα at any of the time points tested (Fig. 2d).
Activation of PKC Isoforms by Bryostatin-1 or TPPB in SH-
SY5Y Neuroblastoma Cells PKC activation was measured by
comparing the cytosol to membrane translocation of PKC
isoforms α, δ, and ε (relative to actin) following treatment
with bryostatin-1 or TPPB. Confluent cultures of SH-SY5Y
neuroblastoma cells were treated with different concentrations
of either bryostatin-1 or TPPB for time points up to 3 h, when
membrane and cytosolic pools of PKCs were isolated by
differential detergent extraction, and Western-blotted for each
individual isoform. Actin was also Western-blotted in each
fraction to ensure equal loading. At 3 h, 10−8, 10−9, and
10−10 M bryostatin-1 significantly increased the activation of
PKC-α in SH-SY5Y cells (**p<0.01) (Fig. 3a); 10−8, 10−9,
and 10−10 M TPPB did not activate PKC-α (Fig. 3a). A time
course activation study of 10−9 M bryostatin and 10−9 M
TPPB showed that 10−9 M bryostatin-1 activated PKC-α at
0.5, 1, and 3 h (**p<0.01) (Fig. 3b); 10−9 M TPPB only
significantly activated PKC-α at 3 h (**p<0.01) (Fig. 3b).
Bryostatin-1 at 10−10 M activated PKC-α at 3 h (**p<0.01);
10−10 M TPPB did not activate PKC-α at any time point
tested. A dose-dependent comparison of bryostatin-1 and
TPPB showed that, at 3 h, PKC-δ was activated by 10−8 M
bryostatin-1 (**p<0.01), 10−9 M bryostatin-1 (*p<0.05), and
10−10 M bryostatin-1 (*p<0.05) (Fig. 4a); TPPB did not
activate PKC-δ at any concentration tested at 3 h (Fig. 4a).
A time course study of 10−9M bryostatin-1 and TPPB showed
that 10−9M bryostatin-1 significantly activated PKC-δ at 0.5 h
(**p<0.01), 1 h (**p<0.01), and 3 h (**p<0.01); by com-
parison, 10−9 M TPPB did not activate PKC-δ at any time
point tested (Fig. 4b). A time course study of 10−10 M
bryostatin-1 and TPPB showed that 10−10 M bryostatin-1
significantly activated PKC-δ at 1 h (*p<0.05) and 3 h
(**p<0.01); by comparison, 10−10 M TPPB did not activate
PKC-δ at any time point (Fig. 4c). A dose-dependent compar-
ison of bryostatin-1 and TPPB showed that, at 3 h, PKC-ε was
activated by 10−8 M bryostatin-1 (*p<0.05), 10−9 M
bryostatin-1 (**p<0.01), and 10−10 M bryostatin-1 (*p<0.05)
(Fig. 5a); TPPB did not activate PKC-ε at any concentration
tested at 3 h (Fig. 5a). A time course study of 10−9 M
bryostatin-1 and TPPB showed that 10−9 M bryostatin-1 sig-
nificantly activated PKC-ε at 0.5 h (**p<0.01), 1 h (**p<
0.01), and 3 h (**p<0.01) (Fig. 5b); by comparison, 10−9 M
TPPB did not activate PKC-ε at any of the time points tested
(Fig. 5b). A time course study of 10−10 M bryostatin-1 and
TPPB showed that 10−10 M bryostatin-1 significantly activated
PKC-ε at 0.5 h (*p<0.01), 1 h (*p<0.01), and 3 h (**p<0.01)
(Fig. 5c); by comparison, 10−10 M TPPB did not activate PKC-
δ at any of the time points tested (Fig. 5c).
Discussion
The presence of Aβ-laden cerebral plaques in AD, a central
feature of Alzheimer’s disease (AD), is thought to contribute
to the disturbances in nerve structure, function, and memory
which characterize AD dementia (Almeida et al. 2005;
Concentration
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Fig. 1 Increase in α-secretase activity induced by different concen-
trations of TPPB and bryostatin-1 in SH-SY5Y neuroblastoma cells for
3 h. Bryostatin-1 significantly induced sAPPα release at 10−7 M (**p<
0.01), 10−8 M (**p<0.01), 10−9 M (*p<0.05), and 10−10 M (*p<0.05).
TPPB also induced sAPPα release, but to a lesser extent, and only at
10−7 M (*p<0.05) and 10−8 M (*p<0.05)
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Hsieh et al. 2006; Selkoe 2002). Aβ plaques are neurotoxic
and thought to provoke detrimental effects on memory,
cognitive function (Ono and Yamada 2011; Zhang et al.
2011), and synaptic organization (Cleary et al. 2005;
Shankar et al. 2008). Paradoxically, normal synaptic activity
generates Aβ (Cirrito et al. 2005; Kamenetz et al. 2003) and
very low (~pM) levels of Aβ enhance synaptic plasticity
(Puzzo et al. 2008). Therefore, while excessive Aβ produces
pathology in AD, very limited APP processing to Aβ may
normally participate in synaptic function (albeit at lower
levels than those seen in AD). Because the disproportionate
formation of Aβ can be prevented by activation of the
α-secretase pathway, agents which activate this pathway
may have important future applications in AD treatment.
There has recently been an intense focus on research gov-
erning the molecular events controlling α-secretase
processing of APP as a powerful prophylactic and therapeutic
approach for AD. α-Secretase processing can be activated by
cholinergic g-protein-coupled receptors (Nitsch et al. 1992),
receptor tyrosine kinases, MAP kinases, PI3-kinase, cAMP
and calcium kinases, and several PKC isoforms (Postina
2012). In particular, activators of the “novel” PKC isoforms
(PKC-δ and PKC-ε) potently activate α-secretase processing
of APP and may represent novel and specific targets for AD
therapy. PKC isoforms exhibit diverse target specificities
reflecting heterogeneous expression in different cell and tissue
types, cell compartment, and duration and mode of activation.
Since PKC activators have emerged as highly potently α-
secretase activators, there has been an intensive investigation
to identify potent and selective PKC-α-secretase activators
with low toxicity and carcinogenicity and high penetration
of the blood–brain barriers.
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Fig. 2 a Time course of α-secretase activity induced by bryostatin-1
and TPPB at 10−7 M in SH-SY5Y neuroblastoma cells. Bryostatin-1
induced a significant release of sAPPα at 3 h (**p<0.01), and TPPB
induced the release of sAPPα at 6 h (*p<0.05). b Time course of α-
secretase activity induced by bryostatin-1 and TPPB at 10−8 M in SH-
SY5Y neuroblastoma cells. Bryostatin-1 induced a significant release
of sAPPα at 3 h (**p<0.01), 6 h (**p<0.01), and 12 h (*p<0.05);
TPPB induced the release of sAPPα at 6 h (*p<0.05). c Time course of
α-secretase activity induced by bryostatin-1 and TPPB at 10−9 M in
SH-SY5Y neuroblastoma cells. Bryostatin-1 induced a significant
release of sAPPα beginning at 0.5 h (*p<0.05), 1 h (**p<0.01), and
3 h (**p<0.01); TPPB induced the release of sAPPα at 3 h (*p<0.05).
d Time course of α-secretase activity induced by bryostatin-1 and
TPPB at 10−10 M in SH-SY5Y neuroblastoma cells. Bryostatin-1
induced a significant release of sAPPα at 3 h (**p<0.01); 10−10 M
TPPB did not significantly induce sAPPα release
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Several AD research groups have investigated PKC acti-
vation as a central regulator of APP processing, AD patho-
physiology, and cognitive impairment (Ruiz-Leon and
Pascual 2001). In AD, brain PKC levels are decreased,
which may partly explain some of the defects in APP
processing that characterize AD (Govoni et al. 1993). In
AD, PKC-β protein levels are reduced, but PKC-α, -β , and
−γ mRNAs were unaffected, consistent with rapid PKC-β
proteolysis (Chachin et al. 1996). AD dementia has also
been associated with lower levels of PKC activation (Wang
et al. 1994). Aβ and APP reduce intra-cerebrellar PKC-ε
levels (de Barry et al. 2010; Hongpaisan et al. 2011; Liron et
al. 2007), PKC phosphorylation (Moriguchi et al. 2006),
and PKC activity (Lee et al. 2004), suggesting a positive
feedback loop of Aβ formation and PKC suppression. Age-
related decreases in PKC may also lead to defects in APP
processing and contribute to AD pathology (Pascale et al.
1998). These findings all support decreased PKC and PKC
hypofunctioning as underlying causes of AD progression.
Consistent with these findings, activation of PKCs (espe-
cially novel isoforms) and α-secretase has been shown to
ameliorate pathophysiology and cognitive impairment in
AD (Ruiz-Leon and Pascual 2001).
PKC isoforms -α, -δ, and -ε potently regulate APP pro-
cessing (Yeon et al. 2001), and differential activation of
these isoforms has important implications for the design of
mechanism-based therapeutics in AD. PKC-α is a “classi-
cal” PKC requiring Ca2+, diacylglycerol, and phospholipid
for activation (Konopatskaya and Poole 2010). PKC-δ is a
“novel” PKC isoform which modulates learning and mem-
ory (Sun and Alkon 2010), which is activated by cis-unsat-
urated fatty acids (Khan et al. 1993) and by 3,4
diphosphatidyl- and 1,3,4 triphosphatidyl-inositol (PdIns)
(Toker et al. 1994). PKC-δ activation by PdIns species
may provide important links between phospholipase C sig-
naling and PKC-δ activation. PKC-δ was originally cloned
from brain tissue (Ono et al. 1987) and is a prominent albeit
heterogeneously distributed PKC isoform in the post-natal
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Fig. 3 a PKC-α translocation induced by different concentrations of
bryostatin-1 and TPPB in SH-SY5Y neuroblastoma cells at 3 h.
Bryostatin-1 significantly induced the translocation of PKC-α at
10−8 M (**p<0.01), 10−9 M (*p<0.05), and 10−10 M (*p<0.05); TPPB
did not induce a significant PKC-α translocation. b Time course of
PKC-α translocation induced by 10−9 M bryostatin-1 or TPPB in SH-
SY5Y neuroblastoma cells at 0.5, 1, and 3 h. A total of 10−9 M
bryostatin-1 significantly induced the translocation of PKC-α at 0.5 h
(**p<0.01), 1 h (*p<0.05), and 3 h (**p<0.01); 10−9 M TPPB only
induced a significant PKC-α translocation at 3 h. c Time course of
PKC-α translocation induced by 10−10 M bryostatin-1 and TPPB in
SH-SY5Y neuroblastoma cells. A total of 10−10 M bryostatin-1 signif-
icantly induced the translocation of PKC-α at 3 h (**p<0.01); 10−10 M
TPPB did not significantly induce PKC-α translocation at any of the
time points tested
b
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(but not PKC-α or PKC-ε) also activates MEK-ERK sig-
naling (Ueda et al. 1996).
PKC-δ plays a specific role in stimulating neuritogenesis in
PC12 cells (O'Driscoll et al. 1995). PKC-ε (Koide et al. 1992),
another “novel” PKC is expressed at high levels in brain
(Mischak et al. 1993; Van Kolen et al. 2008; Wetsel et al.
1992) and has been cited as an important PKC regulating Aβ
and sAPPα ratios (Zhu et al. 2001). PKC-ε activators, like
bryostatin-1, directly enhance cognition (Wang et al. 2008)
and limit dementia in mouse models of AD (Hongpaisan et al.
2011) through several mechanisms which may include
(1) Ca2+ flux, (2) GABA(A)R-regulated post-synaptic cur-
rents, and (3) cholinergic signaling (Van Kolen et al. 2008).
Acute treatment with tetradecanoyl phorbol acetate
(TPA) activates α-secretase via PKC-α (Racchi et al.
2003). Neurons treated with TPA for 24 h down regulated
PKC-α, -β, and -γ but maintained PKC-δ and -ε (Burry
1998). Chronic TPA treatment down regulated PKC-α and
increased PKC-ε expression (Da Cruz e Silva et al. 2009).
Importantly, chronic TPA treatment decreases sAPPα and
increases Aβ formation. Therefore, acute TPA exposure
enhances sAPPα and decreases Aβ; chronic TPA treatment
increases Aβ (Da Cruz e Silva et al. 2009).
PKC-dependent APP modulators remain highly attractive
strategies for AD therapy because of their high potency,
specificity, low potential for carcinogenesis, and high anti-
inflammatory potential (Carpenter and Alexander 2008).
Two important members of this class include bryostatin-1
and TPPB. Bryostatin-1 is a cyclic macrolide lactone mod-
ulator of PKC that occurs at low concentrations (5–25 ppm)
in the marine bryozoan, Bugula neritina, an invasive type of
“sea moss” found in coastal California and Hawaii.
Bryostatin-1, a highly potent PKC activator, enhances cog-
nition and memory consolidation independently of its ability
to stabilize AD-related dementia (Sun and Alkon 2010).
Bryostatin-1 is effective as a chronic activator of APP pro-
cessing, even in cells with AD defects, because it does not
decrease PKC-δ or -ε like phorbol esters and does not lead
to PKC isoform suppression. For example, fibroblasts from
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Fig. 4 a PKCδ translocation induced by different concentrations of
bryostatin-1 and TPPB in SH-SY5Y neuroblastoma cells for 3 h.
Bryostatin-1 significantly induced the translocation of PKCδ at
10−8 M (**p<0.01), 10−9 M (*p<0.05), and 10−10 M (*p<0.05), but
TPPB did not significantly induce PKCδ translocation at any concen-
tration tested. b Time course of PKC-δ translocation induced by
bryostatin-1 and TPPB at 10−9 M in SH-SY5Y neuroblastoma cells.
Bryostatin-1 induced a significant PKC-δ translocation beginning at
0.5 h (**p<0.01), 1 h (**p<0.01), and 3 h (**p<0.01); 10−9 M TPPB
did not significantly induce PKC-δ translocation at any of the times
tested. c Time course of PKC-δ translocation induced by bryostatin-1
and TPPB at 10−10 M in SH-SY5Y neuroblastoma cells. Bryostatin-1
induced a significant PKC-δ translocation beginning at 1 h (*p<0.05)
and 3 h (**p<0.01); 10−10 M TPPB did not significantly induce PKC-δ
translocation at any of the times tested
b
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phorbol ester stimulation (Bergamaschi et al. 1995), while
sub-nanomolar concentrations of Bryostatin-1 dramatically
enhanced the generation of non-amyloidogenic sAPPα
(Nelson et al. 2009). Bryostatin-1 reduces amyloid plaques
(detected as Aß40 and Aß42 in AD) in the brains of trans-
genic AD mice and improved behavioral outcomes and the
rate of death in AD transgenic mice. Bryostatin-1 also
enhances cognition and memory consolidation outside the
settings of AD-dementia models (Sun and Alkon 2010).
Since bryostatin-1 produces neuroprotection in AD animal
models and independently enhances cognition and memory,
it is possible that bryostatin-1 treatment may be able to
restore as well as prevent AD-associated dementia.
By comparison, TPPB is a novel, synthetic cell-
permeable benzolactam PKC activator which has been used
as a standard APP modulator (Kozikowski et al. 2003).
TPPB binds “classical” (with a Ki of 11.9 nM for PKC-α)
and “novel” PKC isoforms to stimulate sAPPα processing
(Kozikowski et al. 2003; Yang et al. 2007). TPPB stimulates
α-secretase in human fibroblasts (AG06848 cells) at con-
centrations as low as 100 nM (10−7 M) to enhance non-
amyloidogenic processing of APP to sAPPα. Currently, the
toxicological properties of TPPB are not fully known. An
important goal in PKC–APP modulator drug design must be
to overcome the potential carcinogenic properties of benzo-
lactams/indolactams because TPPB, like TPA and other
phorbol esters, may still retain tumor-promoting activity
(Kozikowski et al. 2003). Therefore, although benzolactams
like TPPB display reduced tumorigenic activity compared to
phorbol esters (Irie et al. 2004; Nakagawa et al. 2001), this
concern becomes increasingly more significant considering
the relatively high doses (~10−7 M) of TPPB needed to
reach equivalent α-secretase activation as bryostatin-1
which may hamper its use in human AD therapy. There
are, of course, relative factors of availability and cost of
bryostatin-1 versus reduced potency and higher toxicity of
TPPB which can ultimately determine clinical use.
Our current study compared the pharmacokinetics of α-
secretase APP processing and PKC-α, -δ, and -ε isoform acti-
vation by bryostatin-1 and TPPB in SH-SY5Y neuroblastoma
cells. Bryostatin-1 significantly induced sAPPα release from
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Fig. 5 a PKC-ε translocation induced by different concentrations of
bryostatin-1 and TPPB in SH-SY5Y neuroblastoma cells at 3 h.
Bryostatin-1 significantly induced the translocation of PKC-ε at 10−8 M
(*p<0.05), 10−9 M (**p<0.01), and 10−10 M (*p<0.05); TPPB did not
significantly induce PKC-ε translocation at any of the concentrations
tested. b Time course of PKC-ε translocation induced by bryostatin-1
and TPPB at 10−9 M in SH-SY5Y neuroblastoma cells. Bryostatin-1
induced a significant PKC-ε translocation beginning at 0.5 h (**p<
0.01), 1 h (**p<0.01), and 3 h (**p<0.01); TPPB did not significantly
induce PKC-ε translocation at any of the time points tested. c Time course
of PKC-ε translocation induced by bryostatin-1 and TPPB at 10−10 M in
SH-SY5Y neuroblastoma cells. Bryostatin-1 induced a significant PKC-ε
translocation beginning at 0.5 h (**p<0.01), 1 h (**p<0.01), and 3 h
(**p<0.01); 10−10 M TPPB did not significantly induce PKC-ε translo-
cation at any of the time points tested
b
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at 10−7 and 10−8 M. Even at effective doses, the magnitude of
TPPB activation of α-secretase was lower than bryostatin-1.
Time course studies also show that 10−7 M bryostatin-1 signif-
icantly induced sAPPα release by 3 h. TPPB also induced
sAPPα release at 10−7M but required 6 h to significantly induce
sAPPα release at this dose. Bryostatin-1 at 10−8 M significantly
increased sAPPα release at 3, 6, and 12 h; 10−8 M TPPB only
induced significant sAPPα release at 6 h. Bryostatin-1 at 10−9M
significantly increased sAPPα secretion beginning at 30 min
through 3 h, while 10−9 M TPPB was only able to induce the
release of sAPPα at 3 h. Lastly, at 10−10 M, bryostatin-1 signif-
icantly increased sAPPα release at 3 h, where 10−10MTPPB did
not significantly increase sAPPα release. Both time and dose
comparisons indicate that bryostatin-1 induces sAPPα release in
SH-SY5Yneuroblastoma cells at one to two orders ofmagnitude
greater potency and at earlier time points than TPPB. Bryostatin-
1 therefore represents a highly active APP modulator which
could be used as a low-dose therapy for AD.
Novel PKC activators are important candidate treatments for
AD because they activate beneficial APP processing through
α-secretase.We compared how PKC-α (a “classical” PKC), -δ,
and -ε (novel PKC isoforms) were activated in neuroblastoma
cells by bryostatin-1 and TPPB as a function of time and
concentration. Bryostatin-1 significantly induced PKC-α, -δ,
and -ε activation at 10−8, 10−9, and 10−10 M in SH-SY5Y cells.
TPPB, however, was only able to significantly activate PKC-α
at 10−9 M after 3 h. Interestingly, this activation was not seen at
higher doses or at earlier time points. Time course experiments
showed that 10−9 M bryostatin-1 induced a significant and
persistent activation of PKC-α, -δ, and -ε beginning at
30 min and which persisted for at least 3 h. At 10−10 M,
bryostatin-1 also induced PKC-α activation at 3 h; 10−10 M
bryostatin-1 triggered significant PKC-δ activation at 1 h,
which persisted for 3 h. At 10−10 M, bryostatin-1 also triggered
PKC-ε activation by 30 min, which persisted for 3 h. TPPB did
not significantly induce PKC-δ or PKC-ε activation at any
concentration. Although TPPB has been demonstrated to acti-
vate PKC in this cell line (Yang et al. 2007), this effect was seen
with TPPB doses in the order of 10–1,000×g greater than those
used for bryostatin-1 in the current studies. Therefore, when
comparing bryostatin-1 and TPPB, a recognized APP modula-
tor, bryostatin-1 was found to potently activate PKC-ε translo-
cation in SH-SY5Y cells at 10−8, 10−9, and 10−10 (at 3 h).
Bryostatin-1 also appears to be a more active, rapid, and
persistent APP modulator which reflects its greater specificity
toward PKC-δ or PKC-ε isoform activation at low doses.
Conclusions
Here, we found that bryostatin-1 exerted a more rapid, potent,
and sustained activation of APP processing (in particular, the
selective activation of the α-secretase amyloid processing
pathway), which was associated with its more potent and
specific activation of PKC-δ and PKC-ε at low doses. The
further refinement of bryostatin-1 pharmacology in PKC mo-
bilization and α-secretase activation may help move this drug
class more rapidly into clinical treatment for AD.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution License which permits any use, distribution,
and reproduction in any medium, provided the original author(s) and
the source are credited.
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